SVB Leerink Initiates Coverage On Belite Bio with Outperform Rating, Announces Price Target of $25
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Marc Goodman has initiated coverage on Belite Bio (NASDAQ:BLTE) with an Outperform rating and a price target of $25.
July 26, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio has been given an Outperform rating and a price target of $25 by SVB Leerink.
The Outperform rating from SVB Leerink indicates that the analyst expects Belite Bio to do better than the market average. This positive outlook, coupled with a price target of $25, suggests potential upside for the stock, which could attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100